# US 2025/0093353 A1 · Method and system for buoyant-particle-assisted cell therapy > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2025/0093353 A1 - Document ID: US20250093353A1 - Status: Published application - Kind: A1 - Application number: 18/964,694 - Filed: 2024-12-02 - Published: 2025-03-20 - Earliest claimed: 2022-04-01 - Assignees: Akadeum Life Sciences, Inc. - Applicants: Akadeum Life Sciences, Inc. - Inventors: Tiffany Snow; Jonathan Roussey; Casey Wegner; Brandon H. McNaughton - Web page: https://patentgrep.com/patent/US20250093353A1 ## CPC - G01N 33/56972: {White blood cells} - A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) - B01D 21/0084: {Enhancing liquid-particle separation using the flotation principle (flotation in general B03D1/00)} - B03D 1/023: {Carrier flotation; Flotation of a carrier material to which the target material attaches} - C12N 5/0634: {Cells from the blood or the immune system} - G01N 33/5432: {Liposomes or microcapsules} - B01D 2221/10: Separation devices for use in medical, pharmaceutical or laboratory applications, e.g. separating amalgam from dental treatment residues - B03D 2203/003: Biotechnological applications, e.g. separation or purification of enzymes, hormones, vitamins, viruses - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28) - B03D: FLOTATION; DIFFERENTIAL SEDIMENTATION (sedimentation in general B01D21/00; in combination with other separation of solids B03B; sink-float separation B03B5/28; detergents, soaps C11D) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract A system for buoyant-particle-assisted cell therapy includes and/or interfaces with a set of buoyant particles. Additionally or alternatively, the system can include and/or interface with a processing container, a set of processing materials (e.g., buffers, factors, solutions, etc.), and/or any other components. A method for buoyant-particle-assisted cell therapy includes processing the set of cells of interest. Additionally or alternatively, the method can include any or all of: preparing a set of buoyant particles; receiving a sample; and isolating a set of cells of interest from the sample. ## Claims ### Claim 1 A method for buoyancy-assisted production of cells for a cell therapy, the method comprising: producing bound T cells by combining a set of antibodies, a set of buoyant particles, and T cells within a container, wherein the set of buoyant particles are functionalized with moieties for binding to and forming a complex with the antibodies, wherein the bound T cells aggregate at a superior region of the container; culturing the bound T cells in the container to produce daughter cells from the bound T cells, wherein the daughter cells detach from the bound T cells and aggregate at an inferior surface of the container, thereby decreasing exhaustion of the daughter cells due to exposure of the daughter cells to the antibodies; and collecting the daughter cells, wherein the daughter cells are used in the cell therapy. ### Claim 2 (depends on 1) The method of claim 1, wherein in at least a portion of the bound T cells, a single T cell is bound to multiple buoyant particles of the set of buoyant particles. ### Claim 3 (depends on 1) The method of claim 1, wherein the bound T cells are cultured for at least 3 days. ### Claim 4 (depends on 1) The method of claim 1, further comprising performing a selection process by combining the daughter cells with a second set of buoyant particles. ### Claim 5 (depends on 1) The method of claim 1, wherein the daughter cells sink from the superior region of the container to the inferior surface of the container, thereby increasing a spatial separation between the daughter cells and the bound T cells. ### Claim 6 (depends on 1) The method of claim 1, wherein the set of buoyant particles comprises glass beads. ### Claim 7 (depends on 1) The method of claim 1, wherein the set of buoyant particles comprises streptavidin-functionalized buoyant particles. ### Claim 8 (depends on 1) The method of claim 1, wherein a bound T cell in the bound T cells comprises multiple antibodies bound to a buoyant particle of the set of buoyant particles. ### Claim 9 (depends on 8) The method of claim 8, wherein the multiple antibodies comprise a CD3 antibody and a CD28 antibody. ### Claim 10 (depends on 1) The method of claim 1, wherein the set of buoyant particles are submerged within fluid in the container. ### Claim 11 (depends on 1) The method of claim 1, wherein the container comprises a Leukopak bag. ### Claim 12 (depends on 1) The method of claim 1, further comprising transfecting the T cells. ### Claim 13 (depends on 1) The method of claim 1, wherein the container comprises a sealing mechanism configured to separate the superior region of the container from an inferior region of the container. ### Claim 14 A method for buoyancy-assisted production of cells for a cell therapy, the method comprising: performing a first negative selection, comprising: producing bound T cells by combining a first set of buoyant particles and T cells within a container, wherein the T cells comprise a first subset of the T cells and a second subset of the T cells, wherein the first set of buoyant particles are functionalized with moieties for binding to and forming a complex with the second subset of the T cells, wherein the bound T cells aggregate at a superior region of the container; and removing the bound T cells; culturing the first subset of the T cells in the container to produce expanded T cells; performing a second negative selection, comprising: producing second bound T cells by adding a second set of buoyant particles to the container, wherein the expanded T cells comprises a first subset of the expanded T cells and a second subset of the expanded T cells, wherein the second set of buoyant particles are functionalized with moieties for binding to and forming a complex with the second subset of the expanded T cells, wherein the second bound T cells aggregate at a superior region of the container; and removing the second bound T cells; and collecting the first subset of the expanded T cells for the cell therapy. ### Claim 15 (depends on 14) The method of claim 14, wherein the first subset of T cells comprises CD8+ T cells. ### Claim 16 (depends on 14) The method of claim 14, wherein the first subset of T cells CD4+ T cells. ### Claim 17 (depends on 14) The method of claim 14, wherein in at least a portion of the bound T cells, a single T cell is bound to multiple buoyant particles of the first set of buoyant particles. ### Claim 18 (depends on 14) The method of claim 14, wherein the first subset of the T cells is cultured for at least 3 days. ### Claim 19 (depends on 14) The method of claim 14, wherein the container comprises a sealing mechanism configured to separate the superior region of the container from an inferior region of the container. ### Claim 20 (depends on 18) The method of claim 18, wherein the sealing mechanism comprises a valve.